Teprotumumab Improves Thyroid Eye Disease Across Phenotypes

(MedPage Today) -- NEW ORLEANS--Comparable improvements were observed with teprotumumab (Tepezza) between patients with age-related phenotypic I or II thyroid eye disease, according to results from a post-hoc analysis.
At 24 weeks, 81% of...